Agreements

* On June 8, 2013, CRS has entered into a long-term strategic partnership with Bayer HealthCare in clinical drug development. Cooperation will include R&D services for early clinical trials (Phases I-IIa). The two companies have already worked together successfully for several years and the new agreement paves the way for an even broader partnership in order to increase the benefits of this cooperation. CRS will take charge of Bayer HealthCare’s clinical pharmacology units and integrate them into CRS’s network of research centres in Germany. As a result, the CRS Group is widening its range of services to include specialist expertise in cardiovascular and gynaecological indications.